Person Testifying:
   Daniel Paul Perez, President & CEO

Organization:
   FSH Society, Inc. [facioscapulohumeral muscular dystrophy]
   3 Westwood Road, Lexington, MA 02420 USA
   (781) 860-0501, (781) 275-7781 Direct
   (781) 860-0599 fax, e-mail: daniel.perez@fshsociety.org, web: www.fshsociety.org

Date/Time:
   March 30, 2007

Place:
   U.S. Senate, 184 Dirksen Senate Office Building, Washington, DC 20510 USA
   U.S. Senate Committee on Appropriations, Subcommittee on Labor, Health and Human Services, Education and Related Agencies

Regarding:
   FY2008 Appropriations for the National Institutes of Health (NIH) Programs on Facioscapulohumeral Muscular Dystrophy (FSHD) Research.

Summary Including Department, Program or Issue:
   Mr. Perez is a patient who has suffered from facioscapulohumeral muscular dystrophy (FSHD), the second most common form of muscular dystrophy, for the last 45 years. He is a graduate of Harvard College and an internationally renowned patient advocate for muscular dystrophy. He has given 36 congressional testimonies over the last 15 years resulting in a dozen sections of report language instructing the National Institutes of Health (NIH) to increase the portfolio in FSHD. His non-profit FSH Society, Inc. is known worldwide for its highly successful research program yielding many new insights into FSHD and for its work with patients and families.

   Mr. Perez is known by the Director of NIH and well known by the Directors of various institutes of NIH and worldwide research agencies involved with muscular dystrophy. He serves at the behest of Secretary Leavitt and Dr. Zerhouni on the Muscular Dystrophy Coordinating Committee as mandated by the MD CARE Act 2001 and has been intimately involved with this federal advisory committee.

   He will convey the shock and outrage that comes with the knowledge that after all this time and effort, only one out of the twelve NIH institutes responsible for muscular dystrophy research has grants on FSHD and that the lead institute of NIH for dystrophy, NIAMS, has no research grants for FSHD.

   This testimony before the U.S. Senate Committee on Appropriations, Subcommittee on Labor, Health and Human Services, Education and Related Agencies is regarding FY2008 Appropriations for the NIH funding for Facioscapulohumeral Muscular Dystrophy (FSHD) and muscular dystrophy research.

   Mr. Perez is asking for an appropriation of $100 million for the MD CARE Act 2001 for FY2008 to bring muscular dystrophy in line with other diseases with similar cost burden (based on diseases with similar burden listed on NIH Office of the Director disease spending figures). He is requesting $250 million in the 5 years after that. Mr. Perez is also asking for a readjustment of muscular dystrophy funding to make FSHD funding proportional. Right now FSHD receives 4 percent or $1.7 million of the total NIH dystrophy budget. He is asking for $20 million to be appropriated for NIH FSHD research as required under the MD CARE Act 2001 and by the Muscular Dystrophy Research Action Plan submitted to the Congress.
Testimony of Daniel Paul Perez, President & CEO of the FSH Society
Before the U.S. Senate Appropriations, Subcommittee on Labor, Health and Human Services, Education and Related Agencies on the Subject of FY2008 Appropriations for National Institutes of Health (NIH) Research on FSH Muscular Dystrophy (FSHD)
March 30, 2007

Chairman Harkin and Senator Specter, thank you for the opportunity to testify.

I know the budget is operating under the crushing burden of the wars in Iraq and Afghanistan, and the tax cuts to the wealthiest Americans. I am here to remind you that facioscapulohumeral muscular dystrophy (FSHD) is still taking its toll on your citizens.

I am no stranger to this process and FSHD. This will be my 36th congressional testimony in fifteen years. 14 years ago, I first gave testimony in person to U.S. House Representative Natcher and have been back many times since.

FSHD is the second most common dystrophy, a crippling disease causing loss of all skeletal muscle, and it affects 20,000 Americans.

The unique epigenetic structure of FSHD is unprecedented in other genetic disorders and it demands novel approaches and new research groups. There are no free lunches. Investments from small non-profits like the FSH Society and NIH have allowed the initiation of novel and promising research. Our successes are just beginning, we are not there yet and your support has to be continued. It is vital to follow multiple and complementary approaches.

Today, I ask you for three things.

1. Resume the five year doubling of the NIH budget. Appropriate $32.8 billion as required in the NIH Health Reform Act 2006 (P.L. 109-482). At minimum, appropriate a 6.7% annual increase over the next three years to restore funding. Only America has the ability to solve devastating dystrophies. Only NIH can do this. The question is -- does America have the will? Small non-profits like the FSH Society can not shoulder the burden year after year for new and novel research funding. This is what NIH is designed to do. Congress needs to fund it.

2. Tell the Director of NIH to make the Muscular Dystrophy Research Action plan submitted to Congress viable. The MD CARE ACT 2001 authorization needs an appropriation with it. It requires $100 million in FY2008 and $250 million over the next five years for NIH. This will stop dystrophy dead in its tracks and return on investment will be immediate. Tell the Director that the “Pioneer” and “Roadmap” programs have taken money away from peoples’ diseases. Tell him to spend the “Common Fund” directly on research that will effect patients’ lives.

3. Tell the Director that $1.7 million for FSHD does not cut it. The funding for dystrophy is not equitable. The funding for FSHD is abysmal. FSHD research will help solve others diseases such as cancer, autism and diabetes. Tell the Director to assign $20 million for facioscapulohumeral muscular dystrophy (FSHD) research.

Congress has repeatedly asked NIH for a comprehensive portfolio on FSHD. I wrote portions of the MD CARE ACT 2001 with Senator Wellstone. I have served for six years on the Muscular Dystrophy Coordinating Committee (MDCC). I have done everything that the Administration and NIH has asked of me. I implore you to ask the Director why, after all this time and effort, only one of twelve (1/12) NIH institutes covering muscular dystrophy has funded research grants for FSHD.
The war must end and tax cuts must be resolved in 2008. You know, I know and the American public knows that America has fallen behind when it comes to health care and biomedical research.

Fourteen years ago, I was able to walk into the U.S. House Rayburn Office building and stand to deliver my testimony. Three days ago, I appeared there again and delivered testimony from my wheelchair. Congress knows what it needs to do, end the wars, repeal the tax cuts to the wealthiest Americans and start rebuilding biomedical research and great universities that have suffered great losses in researchers, research and research funding and that are now in crisis. Stop the politics. Stop victimizing the sick and dying. Stop telling the victims it is their responsibility and correct your congressional actions. Congress must fund research now.

We are waiting.
While we wait, people like me are losing our battles with FSHD.
While we wait, we are losing our quality of life.
Research must be funded and hope rekindled.
I ask you to fund NIH, fund muscular dystrophy, fund FSHD.
I will answer any questions.

Facts on FSHD and NIH funding on FSHD
Facioscapulohumeral Muscular Dystrophy

FSHD is the second most prevalent adult muscular dystrophy. It affects 20,000 Americans. For men, women, and children the major consequence of inheriting FSHD is a lifelong progressive and severe loss of all skeletal muscles. FSHD is simply a most terrible and crippling disease. It is genetically transmitted to children so it affects entire family constellations.

People who have FSHD must cope with continuing, unrelenting, unpredictable and never-ending losses. The most unlucky, those who are affected from birth, are deprived of virtually all the ordinary joys and pleasures of childhood and adolescence. But no matter at which stage of life the disease makes itself known, there is never after that any reprieve from continuing loss of physical ability, or ever for a moment relief from the physical and emotional pain that FSHD brings in its train. Every morning, FSHD sufferers wake up to face the reality that neither a cause for their disease nor any treatment for it has yet been found.

Insidiously and systematically, FSHD denies a person the full range of choices in life. FSHD affects the way you walk, the way you dress, the way you work, the way you wash, the way you sleep, the way you relate, the way you parent, the way you love, the way and where you live, and the way people perceive and treat you. You cannot smile, hold a baby in your arms, close your eyes to sleep, run, walk on the beach, or climb stairs. Each new day brings renewed awareness of the things you may not be able to do the next day. This is what life is for tens of thousands of people affected by FSHD worldwide.

The MD-CARE Act, P.L. 107-84 and the NIH

After ten years of our testifying, begging and pleading for help, the Congress enacted the Muscular Dystrophy Community Assistance, Research and Education Amendments of 2001 (the MD-CARE Act, Public Law 107-84). Both the Senate and House acted with force and clarity to mandate the NIH and other applicable federal agencies, to immediately expand and intensify research on all forms of muscular dystrophy. The MD-CARE Act declared that: 1.) the Director of the NIH work with the Directors of the National Institute of Arthritis and Musculoskeletal Disorders (NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS) and the National
Institute of Child Health and Human Development (NICHD) and others to expand and intensify research on all nine types of dystrophy described in the Act; 2.) Centers of excellence for research be established for all nine types of dystrophy; 3.) a MDCC with two-thirds government and one-third public members be established to coordinate activities across the NIH and other national research agencies on all forms of dystrophy; and; 4.) the MDCC must submit a research action plan for conducting, and supporting research and education for all nine types of dystrophy. The MD-CARE Act also requires annual updates on research funding amounts by the Department of Health and Human Services (DHHS) for Duchenne, Myotonic, FSHD and other muscular dystrophies.

How is FSHD Doing in 2007, Six Years After the MD CARE Act was Passed?

The Act mandates the Director to intensify efforts and research in the muscular dystrophies across the NIH. However, all nine types of dystrophy have not benefited and FSHD is certainly falling far behind.

Centers of excellence otherwise instituted as cooperative research centers (U54s) have not been established for all nine types of muscular dystrophy. FSHD has very little presence in the current Wellstone MD Cooperative Research Centers landscape. The NIH now has six Wellstone MD CRCs, which are approximately equivalent to 31 basic research grants (R01). One-quarter of one Wellstone MD CRC, and two-fifths of another Wellstone MD CRC or three R01 grant equivalents have direct relevance to FSHD.

We applaud Dr. Stephen Katz, Director, NIAMS and Chairman of the MDCC, and John Porter, Program Director Muscular Dystrophy, NINDS and Executive Secretary MDCC, for their extraordinary comprehension, accuracy and for the speed in which the NIH Action Plan for Muscular Dystrophy was researched, compiled, written, and approved. The NIH is making significant investments to understand muscular dystrophy research needs and has made excellent choices in recruiting program staff with the ability to understand the extremely complex nature of muscular dystrophy. The plan was submitted two and a half years ago and many of the items require lead time and require increased funding. However, to this day, the NIH reports difficulty in growing and expanding its FSH muscular dystrophy research portfolio.

**National Institutes of Health (NIH) Muscular Dystrophy Dollars by Institute FY2006**

**Source:** NIH/OD Budget Office (Dollars in millions)

- Participating ICs FY 2006 Actual
- NIAMS 16.6
- NINDS 12.7
- NICHD 4.8
- NHLBI 2.3
- NIA 1.9
- NCRR 0.8
- NCI 0.5
- NHGRI 0.4
- NEI, NIMH, FIC, OD 0.0

**NIAMS**

In fy2006, NIAMS spent $311,059 on FSHD and $16,575,863 on all muscular dystrophy. This comprises 74 projects, including three Wellstone MD CR centers. FSHD was 1.9 percent of NIAMS dystrophy funding.
No research grants, one research contract for FSHD, the National Registry for myotonic and facioscapulohumeral muscular dystrophy for $310,559 and one conference grant for $500.
NIAMS funding for facioscapulohumeral muscular dystrophy went up by $15,171.
Total funding for muscular dystrophy by NIAMS decreased over the year by 3.3%.
This should be shocking to anyone reading this report; NIAMS is the leading institute for muscular dystrophy at the NIH.

NINDS
In fy2006, NINDS spent $1,421,596 on FSHD and of $12,696,674 on all dystrophy. 39 projects, including two Wellstone CR centers were funded. FSHD was 11.1 percent of NINDS muscular dystrophy funding.
Three research grants, one intramural grant, and one-quarter of a Wellstone CR center for facioscapulohumeral muscular dystrophy.
NINDS funding for facioscapulohumeral muscular dystrophy went up by $61,666.
Total funding for muscular dystrophy by NINDS increased over the year by 6%.
The FSHD boat is sinking in the rising tide, concerning to anyone reading this report.

NICHD
In fy2006 NICHD spent $0 on FSHD and of $4,817,582 on all dystrophy. 19 projects, including three Wellstone MD CR centers were funded. FSHD was zero percent of NICHD dystrophy funding.
Total funding for FSHD by NICHD decreased by 100% to zero dollars.
Total funding for dystrophy by NICHD increased over the previous year by 1%.
This is due to the shift to a more accurate and better representation of FSHD research from NICHD. It should be an extremely serious concern to children with FSHD.

NHLBI
In fy2006, NHLBI spent $0 on FSHD and $2.3 million on dystrophy. FSHD was zero percent of NHLBI fy2006 dystrophy funding.
Total funding for FSHD by NHLBI remained at zero dollars.
This should be of grave concern as respiratory insufficiency and failure is a growing cause of death in FSHD.

National Institutes of Health (NIH) Appropriations History

Source: NIH/OD Budget Office & NIH OCPL (Dollars in millions)

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>NIH Overall Dollars</th>
<th>MD Research Dollars</th>
<th>FSHD Research Dollars of MD</th>
<th>FSHD %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>$17,821</td>
<td>$12.6</td>
<td>$0.4</td>
<td>3%</td>
</tr>
<tr>
<td>2001</td>
<td>$20,458</td>
<td>$21.0</td>
<td>$0.5</td>
<td>2%</td>
</tr>
<tr>
<td>2002</td>
<td>$23,296</td>
<td>$27.6</td>
<td>$1.3</td>
<td>5%</td>
</tr>
<tr>
<td>2003</td>
<td>$27,067</td>
<td>$39.1</td>
<td>$1.5</td>
<td>4%</td>
</tr>
<tr>
<td>2004</td>
<td>$27,887</td>
<td>$38.7</td>
<td>$2.2</td>
<td>6%</td>
</tr>
<tr>
<td>2005</td>
<td>$28,494</td>
<td>$39.5</td>
<td>$2.0</td>
<td>5%</td>
</tr>
<tr>
<td>2006</td>
<td>$28,587</td>
<td>$39.9</td>
<td>$1.7</td>
<td>4%</td>
</tr>
<tr>
<td>2007</td>
<td>$28,587est</td>
<td>$39.9est</td>
<td>$1.7est</td>
<td>4%</td>
</tr>
<tr>
<td>2008</td>
<td>$28,587est</td>
<td>$39.6est</td>
<td>$1.7est</td>
<td>4%</td>
</tr>
</tbody>
</table>